Dr. Ramalingam on the Activity of Osimertinib Combinations in NSCLC

Video

In Partnership With:

Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses the activity of osimertinib (Tagrisso) in combination with other agents in EGFR-mutant non–small cell lung cancer (NSCLC).

Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses the activity of osimertinib (Tagrisso) in combination with other agents in EGFR-mutant non—small cell lung cancer (NSCLC).

Resistance mechanisms to osimertinib can manifest through the activation of MET and MEK, says Ramalingam. As such, investigators are pairing osimertinib with some of the specific inhibitors against MET and MEK.

At the 2019 AACR Annual Meeting, there were 2 presentations on this topic. Lecia V. Sequist, MD, MPH, of Massachusetts General Hospital presented data on the combination of osimertinib with a MET inhibitor. Ramalingam presented data with osimertinib combined with a MEK inhibitor. Although the patient sample size is relatively small, investigators are seeing response rates ranging from 25% to 45% with these combinations. Moreover, the median duration of response seems to be in the upper 7 to 8 months. Seeing as these combinations can help combat resistance to osimertinib, they need to be studied further, concludes Ramalingam.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute